


May 14, 2020

Re: SECURE-IBD COVID-19 weekly update #10


Dear Colleagues,

It's quite sobering that the number of reported COVID-19 cases reported to SECURE-IBD has now surpassed the 1000 mark. As of May 12th, colleagues from around the world (42 different countries) have reported a total of 1074 cases of confirmed COVID-19 in IBD patients. On the other hand, this is a remarkable statement about the highly collaborative nature of our international IBD community. We have really come together to generate rapid and reliable data necessary to inform care in the midst of this horrible pandemic.

Please log on to our website at www.covidibd.org to check out the interactive map, where you can visualize the geographic location of reported cases, hospitalizations, and mortality. More information including a breakdown of cases by age, gender, disease type, comorbidities, and medication use is also publically available at www.covidibd.org. Advancing age, number of comorbidities, and smoking status continue to be the major drivers of COVID-19 related mortality and other indicators of a more severe disease course. Oral steroid use continues to be the largest medication-associated risk factor. **Next week, we hope to share data from multivariable analyses.** Going forward, we will continue to update our website on a weekly basis.



Interactive web-based map:
<http://covidibd.org/map/>



Please spread the word about SECURE-IBD and share this newsletter with all of your colleagues, locally, nationally, and internationally.

You may download flyers translated into 17 languages at <https://covidibd.org/press/>

Frequently Asked Questions

What is SECURE-IBD? Surveillance Epidemiology of Coronavirus) Under Research Exclusion (**SECURE-IBD**) is an international, pediatric and adult registry to monitor and report on outcomes of COVID-19 occurring in IBD patients. The

registry contains only de-identified data, in accordance with [HIPAA Safe Harbor De-Identification standards](#). The UNC-Chapel Hill Office for Human Research Ethics has determined that storage and analysis of de-identified data does not constitute human subjects research as defined under federal regulations [45 CFR 46.102 and 21 CFR 56.102] and does not require IRB approval.

How can a provider report a case? We encourage **all IBD providers to report all cases of confirmed COVID-19** in IBD patients, regardless of severity. Reporting should take at most 5 minutes. Please report only confirmed COVID-19 cases, and report after a minimum of 7 days from COVID diagnosis and sufficient time has passed to observe the disease course through resolution of acute illness or death. **To report a case of coronavirus, click [here](#)**

Who is organizing this project? This project is being led by Drs. Michael Kappelman (Pediatric Gastroenterologist) and Erica Brenner (Pediatric Gastroenterology fellow) at the University of North Carolina at Chapel Hill and Dr. Ryan Ungaro (Gastroenterologist) and Dr. Jean-Frederic Colombel (Gastroenterologist) at the Icahn School of Medicine at Mount Sinai, New York.

Are there any partnering organizations/societies? Official partners include the Crohn's & Colitis Foundation, the International Organization for the Study of IBD (IOIBD), the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN), the European Crohn's and Colitis Organisation (ECCO), the Asian Organization for Crohn's & Colitis, and the Pan American Crohn's and Colitis Organisation (PANCCO). We also acknowledge the promotional support of many local/regional societies and pharmaceutical companies as detailed on www.covidibd.org.



European
Crohn's and Colitis
Organisation



Please visit us at www.covidibd.org for updated information or to report a case.

If you have any questions, please reach out to COVID.IBD@unc.edu.

Through worldwide collaboration, we can make a large difference!

Best,

Mike, Erica, Jean-Fred and Ryan

Advisory Committee Members

North America: Jim Lewis and Gil Kaplan
Nursing and Advanced Practitioners: Michele Kissous-Hunt
Europe: Walter Reinisch and Jean-Francois Rahier
Asia: Siew Ng
S. America: Flavio Steinwurz
Australia/New Zealand: Richard Gearry
Industry: Irene Modesto
IOIBD: Marischka Konings